Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria

Cytometry Part A

Volumn 79 A, Issue 5, 2011, Pages 375-382

  Pajor, Gabor ^a   Somogyi, Laszlo ^a   Melegh, Bela ^a   Alpar, Donat ^a   Kajtar, Bela ^a   Farkas, Laszlo ^a   Kneif, Maria ^a   Bollmann, Daniel ^b   Pajor, Laszlo ^a   Sule, Norbert ^c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Institute of Pathology   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Automation; Bladder cancer; CK7 immunophenotyping; Diagnostic cut off value; Targeted FISH

Indexed keywords

ARTICLE; BLADDER TUMOR; CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; MALE; PATHOLOGY; UROTHELIUM;

CARCINOMA; FEMALE; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79955164738     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21065     Document Type: Article

References (30)

1. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urol 2006; 67: 25.
2. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008; 2: 212.
3. Lotan YRoehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder a decision analytical approach. J Urol 2002; 167: 75.
4. Olaf PJVrooman, Alfred Witjes J. Urinary markers in bladder cancer. Eur Urol 2008; 53: 909.
5. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168: 1950.
6. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167: 2001.
7. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, III, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urol 2005; 66: 35.
8. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget. Multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2: 116.
9. Pycha A. FISH: A tool we really need? Eur Urol 2007; 52: 630.
10. Gudjónsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, Lundberg LM, Liedberg F, Grabe M, Månsson W. The Value of the UroVysion® Assay for Surveillance of Non-Muscle-Invasive Bladder Cancer. Eur Urol 2008; 54: 402.
11. Marín-Aguilera M, Mengual L, Ribal MJ, Burset M, Arce Y, Ars E, Oliver A, Villavicencio H, Algaba F, Alcaraz A. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogen 2007; 173: 131.
12. Zellweger T, Benz G, Cathomas G, Mihatsch MJ, Sulser T, Gasser TC, Bubendorf L. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006; 119: 1660.
13. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn 2009; 11: 148.
14. Riesz P, Lotz G, Páska C, Szendrôi A, Majoros A, Németh Z, Törzsök P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 2007; 13: 187.
15. Lukas Bubendorf. Editorial comment on: The value of the UroVysion® assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007; 54: 407.
16. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y, Friberger A, Kidron D, Kaplan E, Lew S, Leibovitch I. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urol 2005; 66: 1354.
17. Reid-Nicholso MD, Ramalingam P, Adeagbo B, Cheng N, Peiper SC, Terris MK. The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. Mod Pathol 2009; 22: 119.
18. Chuang KL, Chuang HC, Ng KF, Chang YH, Wu CT, Chuang CK, Liao SK, Pang ST. Urinary fluorescence in situ hybridization assay for detecting urothelial carcinoma in Taiwanese patients. BJU Int 2010; 105: 1413.
19. Pajor G, Sule N, Alpar D, Kajtar B, Kneif M, Bollmann D, Somogyi L, Pajor L. Increased efficiency of detecting genetically aberrant cells by UroVysion test on voided urine specimens using automated immunophenotypical preselection of uroepithelial cells. Cytometry Part A 2008; 73A: 259.
20. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11.
21. Schaafsma HE, Ramaekers FC. Cytokeratin subtyping in normal and neoplastic epithelium: Basic principles and diagnostic applications. Pathol Annu 1994; 29: 21.
22. Bibbo M, Kern WH. Comprehensive cytopathology, 3rd ed, Chapter 15. In:Bibbo M, Wilbur, DC, editors. Saunders Elsevier.
23. Dewald G, Stallard R, Al Saadi A, Arnold S, Bader PI, Blough R, Chen K, Elejalde BR, Harris CJ, Higgins RR, Hoeltge GA, Hsu WT, Kubic V, McCorquodale DJ, Micale MA, Moore JW, Phillips RM, Scheib-Wixted S, Schwartz S, Siembieda S, Strole K, VanTuinen P, Vance GH, Wiktor A, Zinsmeister A, et al. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. Am J Med Genet 1998; 76: 318.
24. Ferra S, Denley R, Herr H, Dalbagni G, Jhanwar S, Lin O. Reflex UroVysion testing in suspicious urine cytology cases. Cancer Cytopathol 2009; 117: 7.
25. Bollmann D, Bollmann M, Bankfalvi A, Heller H, Bollmann R, Pajor G, Hildenbrand R. Quantitative molecular grading of bladder tumours: A tool for objective assessment of the biological potential of urothelial neoplasias. Oncol Rep 2009; 21: 39.
26. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169: 2101.
27. Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, Montironi R, Tan PH, Zheng S, Baldridge LA, Cheng L. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol 2007; 3: 186.
28. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, Huland H. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003; 92: 911.
29. Moore DH, II, Epstein L, Reeder J, Wheeless L, Waldman FM. Interlaboratory variability in fluorescence in situ hybridization analysis. The NCI Bladder Tumor Marker Network. Cytometry 1996; 25: 125.
30. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 208; 15: 279.